Quarterly Activities/Appendix 4C Cash Flow Report
Released
Released
Announcement PDF
ASX: TTX
ABN: 72 607 771 077
Q2 FY26
QUARTERLY
ACTIVITIES
REPORT
Q2 FY26 QUARTERLY ACTIVITIES REPORT
1
Tetratherix’s strategic partner BioOptix signs a development agreement with Alcon
Tetratherix’s strategic partner, BioOptix, Inc. (BioOptix), a US-based ophthalmic
biomaterials company that is using Tetratherix’s Tetramatrix™ platform intended to
address unmet needs in surgical workflows and ophthalmic care.
BioOptix has entered into a new strategic partnership with Alcon Research, LLC (Alcon).
Under the terms of the agreement, Alcon has agreed to provide milestone-based
development funding to complete a range of specific preclinical studies. The results of
these preclinical studies will form an integral part of the medical device dossier for future
regulatory submissions and market clearances.
Tutelix Cohort 2 patient recruitment and treatment is progressing as planned, following
successful first in human implantation in Q1 FY26
Tetratherix’s joint venture, Tutelix, includes industry-leading clinicians to commercialise a
derivative product from Tetramatrix™ platform technology for interventional urology.
Cohort 2 includes a second site in Melbourne, with patients recruited and being treated.
This allows Tetratherix to assess the clinical usability of the technology with multiple
principal investigators in addition to the Gold Coast site.
Cohort 1 patients have achieved the six months follow up time point with no reported
adverse events or any safety concerns. MRI imaging shows early indication of resorption
whilst the spacing structure remains anatomically in place.
Bone regeneration - Tegenix and TegenEOS development on track for FDA 510(k)
clearance
Tegenix is the first product developed utilising Tetramatrix™ platform technology, and is an
innovative carrier designed to be mixed with a broad array of bone graft materials for dental
and oral applications.
Tegenix animal study implantation has been completed and final report from the contract
research organisation, NAMSA, is under development.
TegenEOS is a bone graft extender for orthopaedic applications that is developed with the
Tetramatrix™ platform technology and can be mixed with different active human derived
demineralised bone matrix.
TegenEOS animal study implementation has commenced with final timepoint expected in
Q3 FY26.
Sydney, Australia 28 January 2026. Tetratherix Limited (ASX: TTX) (Tetratherix) is pleased
to release its Appendix 4C and quarterly activities report for the period ended 31 December
2025.
KEYHIGHLIGHTS FORTHE QUARTER (Q2 FY26)
ASX:TTX | ABN: 72 607 771 077
ASXANNOUNCEMENT JANUARY28, 2026
Q2 FY26 QUARTERLY ACTIVITIES REPORT
2
Advanced and Overseas Finding (AOF) eligibility has been confirmed by AusIndustry
for FY25, FY26 and FY27 for inclusion in Tetratherix’s R&D tax incentive.
On 23 December 2025, AusIndustry (Department of Industry, Science and Resources)
confirmed that Tetratherix’s application for the development of Tegenix for regenerative
dental treatment has been assessed as eligible under the AOF for the R&D tax incentive.
This allows Tetratherix to claim overseas expenditure in bone regeneration activities in
addition to Australian based activities.
Updates to Board of Directors effective 15 December 2025
Peter Gray has been appointed as an independent non-executive director to fill the
vacancy following David Bottomley’s retirement as a non-executive director.
Peter Gray is the co-founder of Zip Co (ASX: ZIP), a leading Australian fintech innovator.
Drawing on more than 30 years of experience in financial services, Mr Gray brings
extensive expertise in building and scaling innovative businesses within highly regulated
environments. His career includes seven years as an ASX director, he is recognised for his
ability to balance entrepreneurial ambition with disciplined governance.
David Bottomley has retired as a non-executive director of Tetratherix. He has been a
long-term supporter of Tetratherix, initially as an early-stage investor and, since March
2020, a non-executive director. Mr Bottomley and his related entities remain significant
shareholders in Tetratherix.
Jacob Pfeffer has been appointed as Company Secretary. Mr Pfeffer has practised at
leading Australian and English law firms and acted as legal advisor to Tetratherix and the
Board during the IPO and ASX Listing in June 2025. He has held the position of General
Counsel since October 2025.
Tetratherix has commenced construction of its additional advanced manufacturing
facility at its Alexandria campus in NSW
The second campus facility is designed to further expand production of Tetratherix’s
synthetic polymer platform and finished goods inventory to meet anticipated global
demand.
The facility is designed for scalability, supporting near-term bone regeneration products
and future expansion into additional clinical indications.
KEYHIGHLIGHTS FORTHE QUARTER (Q2 FY26)
ASX:TTX | ABN: 72 607 771 077
ASXANNOUNCEMENT JANUARY28, 2026
Q2 FY26 QUARTERLY ACTIVITIES REPORT
3
Strong cash on hand position $A21.6 million as at 31 December 2025, with zero debt
financing.
$0.9 million cash inflows for Q2, $1.3 million H1 FY26 driven by Industry Growth Program
(IGP) grant and interest income.
($4.1) million cash outflows for Q2, ($8.3) million H1 FY26 in line with Tetratherix’s use of
funds. Key drivers are continued investment in R&D programs, particularly bone
regeneration (Tegenix and TegenEOS products), capital expenditure for Tetratherix’s new
advanced manufacturing facility and ongoing listing and working capital expenditure.
($0.8) million H1 FY26 for establishment of a bank guarantee security deposit on the new
lease for Tetratherix’s manufacturing upscale.
Tetratherix is in a strong position to continue its focus on investment in research and
development and expansion of its advanced manufacturing capabilities with its closing
cash balance in line with prospectus assumptions.
In accordance with ASX Listing Rule 4.7C.3, Tetratherix advises that an amount of $336K was
paid during the quarter to related parties and associates as disclosed in item 6.1 of the
Appendix 4C. These payments comprised of: $286K for executive and non-executive directors’
salaries, superannuation, and $50K (including GST) in directors’ fees paid to entities
associated with directors. For H1 FY26, payments to related parties and associates amounts to
$1.1 million.
TETRATHERIX FINANCIALCOMMENTARY
ASX:TTX | ABN: 72 607 771 077
“Tetratherix is proud to continue to deliver on the commitments outlined in our
prospectus. In Q2, we advanced the development of ophthalmic biomaterial
technologies with our joint venture partner BioOptix Inc signing a
development agreement with Alcon. Construction has commenced on our
new advanced manufacturing facility in Alexandria, designed to support near-
term dental applications and our longer-term pipeline as we progress clinical
programs in tissue spacing and tissue healing. Earlier this month we
confirmed readiness for commercialisation of our dental application, Tegenix,
by entering into a global exclusive distribution and supply agreement with the
market leader Henry Schein. These achievements reflect our unwavering
commitment to innovation, growth and delivering world-class solutions.”
Will Knox, CEO of Tetratherix
ASXANNOUNCEMENT JANUARY28, 2026
Q2 FY26 QUARTERLY ACTIVITIES REPORT
4
TetraDerm clinical trial advances to third and final cohort.
TetraDerm has been developed using the Tetramatrix™ platform technology and can be used
in any surgical incision site to reduce scarring.
On 13 January 2026 Tetratherix announced the successful completion of the second safety
review meeting of the second cohort of the TetraDerm clinical trial that is evaluating the
product’s ability to prevent scar formation in surgical incisions.
9 patients in the second cohort of the TetraDerm clinical trial have successfully completed
their 6 week follow up assessments.
No procedural or technical adverse events have been observed or reported. This confirms
the differentiated and market leading safety profile of the product.
Based on the clinical observations from the first and second cohorts of patients, the principal
investigator, Dr Drew Cronin, will begin patient enrolment for the third cohort in Q3 FY26.
Tetratherix executes global distribution and supply agreement with Henry Schein
confirming its commercialisation readiness.
Henry Schein, Inc. (Nasdaq: HSIC) (Henry Schein) is the world’s largest provider of health-
care solutions to office based dental and medical practitioners.
On 19 January 2026, Tetratherix announced the execution of a global exclusive distribution
and supply agreement with Henry Schein, confirming a clear and executable pathway for
Tetratherix’s first product commercialisation.
The global exclusive distribution agreement is the next step in the partnership detailed in
the Tetratherix prospectus for Tegenix - the Tetratherix’s universal bone regeneration
technology.
The agreement confirms Henry Schein as the distribution partner for Tegenix, Tetratherix’s
initial product for dental surgery.
The agreement covers initial and renewal terms, which are subject to agreed minimum
purchase quantities, and facilitates immediate access for Henry Schein’s established
global sales and distribution network.
Tetratherix will strategically and deliberately launch Tegenix based on a market seeding
program, ensuring controlled early adoption, clinician engagement and robust post-market
feedback.
H2 FY26 KEYBUSINESS PRIORITIES
ASX:TTX | ABN: 72 607 771 077
ASXANNOUNCEMENT JANUARY28, 2026
Q2 FY26 QUARTERLY ACTIVITIES REPORT
5
Tegenix and TegenEOS regulatory clearance path is to progress as planned for FDA
pre-clinical studies, with expected timelines on track for product commercialisation in
FY27.
These FDA-510(k) clearances will enable Tetratherix to continue its commercialisation
activities under its bone regeneration franchise with its corporate partners.
TetraDERM Cohort 3 initiation in the fast-growing segment of the plastic and
reconstructive surgical market.
Patient recruitment in the Cohort 3 of the TetraDerm clinical trial has been initiated.
Tutelix joint venture capital raising and data readout meeting primary end point for
patients in Australia pilot clinical trial.
Tutelix joint venture aims to secure capital funding for continued investment in clinical
studies and regulatory activity.
Progression of pilot clinical trial, with remaining patients completing their scheduled
radiation therapy.
BioOptix strategic partnership progressing with completion of pre-clinical studies.
Optelex pre-clinical animal studies are expected to be completed in H2 FY26 by an
independent contract research organisation.
Advanced manufacturing facility fit out to continue.
Relocation of Tetratherix’s headquarters, expanded R&D laboratory and manufacturing
facility is anticipated in H2 FY26.
H2 FY26 KEYBUSINESS PRIORITIES (CONT.)
ASX:TTX | ABN: 72 607 771 077
ASXANNOUNCEMENT JANUARY28, 2026
Q2 FY26 QUARTERLY ACTIVITIES REPORT
6
ROADMAPEXECUTION STATUS UPDATE
ASX:TTX | ABN: 72 607 771 077
Investor Hub
Tetratherix has launched its Investor Hub platform, providing existing and prospective
shareholders with real‑time access to ASX announcements, reports and presentations. You
can visit the Tetratherix Investor Hub at: https://investors.tetratherix.com/link/PdxnJP
Authorised for release by CEO and CFO.
For further information contact:
Jacob Pfeffer
General Counsel | Company Secretary
+61 425 194 200
jacob.pfeffer@tetratherix.com
https://tetratherix.com/
ASXANNOUNCEMENT JANUARY28, 2026
7 ASX:TTX | ABN: 72 607 771 077
Tetratherix (Tetratherix) is an Australian medical technology company pioneering advanced
biomaterial solutions to transform how complex diseases are treated. Our proprietary polymer
platform enables the targeted delivery of cells, drugs, and biologics, unlocking new potential
across oncology, regenerative medicine and more. Tetratherix combines deep scientific
innovation with real-world clinical impact; underpinned by a novel business model designed for
global scalability and embedded collaboration with partners and healthcare systems around
the world.
Overview of Tetratherix’s current product portfolio
Tetramatrix is Tetratherix’s current core platform technology. This platform technology is safe
and clinically modular and therefore used to co-develop multiple products in partnership with
leading medical companies. The overarching aim to use the Tetramatrix platform technology
in developing multiple products is to treat patients faster, cheaper, and safer. The current
portfolio of products under development with Tetramatrix spans several large near-term
commercial opportunities that are grouped into three franchises:
TM
TM
TM
Bone regeneration: relates to the utility of theTetramatrix platform’s technology to develop
products to support bone repair in dental and orthopaedic applications.
TM
Tissue spacing: relates to the utility of the Tetramatrix platform technology to develop
products to generate space between two tissues or organs either to support surgical access for
ophthalmic applications or to reduce side effects to surrounding tissue and organs during
cancer treatment; and
TM
Tissue healing: relates to the utility of the Tetramatrix platform technology to develop
product for use during any open surgical intervention to reduce scar formation at the incision
site.
TM
Tissue Healing
Tissue Spacing
Bone Regeneration
Bone graft extender for
dental surgeries
Flowable bone graft
extender for orthopaedic
applications
Prostate Spacer for
radiation therapy
Spacer during
cataract surgeries
Intraoperative solution to reduce scar
formation after surgeries
SEE MORE ATWWW.TETRATHERIX.COM
ASXANNOUNCEMENT JANUARY28, 2026
ABOUT TETRATHERIX
8 ASX:TTX | ABN: 72 607 771 077
This announcement may contain forward-looking statements which may be identified by words
such as “believes”, “considers”, “could”, “estimates”, “expects”, “intends”, “may”, and other
similar words that involves risks and uncertainties. Such statements are not guarantees of
future performance and involve known and unknown risks, uncertainties, assumptions and
other important factors, many of which are beyond the control of Tetratherix or its Directors and
management and could cause Tetratherix’s actual results and circumstances to differ
materially from the results and circumstances expressed or anticipated in these statements.
The Directors cannot and do not give any assurances that the results, performance, or
achievements expressed or implied by the forward-looking statements contained in this
announcement will actually occur and investors are cautioned not to place undue reliance on
these forward-looking statements.
FORWARD LOOKING STATEMENTS
ASXANNOUNCEMENT JANUARY28, 2026
REF Comment
1 - 4
R&D costs include specific projects, directly attributable staff, research and laboratory costs,
trademarks, patent filing, and upkeep. Specific breakdown by project as follows
1
Bone Regeneration: activity focused on preparation for FDA clearance for Tegenix and TegenEOS, with
spending front weighted in FY26
2 Tissue Healing: ongoing clinical trial and pipeline development for TetraDerm
3 Tissue Spacing: relates to Optelex clinical trials. Noting Tutelix R&D is funded by the joint venture.
4 Precision Medicine: No significant expenditure
5
Manufacturing expansion: a new lease was signed in August 2025. Capital expenditure investment has
commenced to commission our advanced manufacturing facility.
6
Listed company costs: Reflects board remuneration, audit fees, share registry, directors’ and officers’
insurance and company secretary services.
7 IPO costs: All invoices have now been paid; in line with prospectus assumptions.
8 Working capital: Includes staff (ex R&D), interest, and general operating expenses
9
UOF proceeds of $33.2m includes $8.2m existing cash on hand as at 30/4 as per prospectus plus $25
million capital raise funding.
$21.6m Closing cash balance as at 31 December 2025.
May 2025- December 2025 cumulative cash outflows total ($11.7) million including ($4.0) million for Q2
FY26
$3.3 million from the Industry Growth Program (IGP) grant, with payments expected across FY26 and
FY27 is an upside to Tetratherix’s UOF and is not included in the appendix 1 table. The co-funding will
enable further investment in additional R&D programs and advanced manufacturing.
For H1 FY26, $0.7 million has been received for IGP per contract milestones
In accordance with ASX Listing Rule 4.7C Tetratherix provides the following use of funds (UOF) information:
APPENDIX 1 USE OF FUNDS INFORMATION
SUBJECTTO LISTING RULE 4.7C
9 ASX:TTX | ABN: 72 607 771 077
Name of entity
ABN Date
72 607 771 077 Dec 31, 2025
APPENDIX 4C QUARTERLYCASH FLOW REPORTFOR
ENTITIES SUBJECTTO LISTING RULE 4.7B
10 ASX:TTX | ABN: 72 607 771 077
APPENDIX 4C QUARTERLYCASH FLOW REPORTFOR
ENTITIES SUBJECTTO LISTING RULE 4.7B (CONT.)
11 ASX:TTX | ABN: 72 607 771 077
APPENDIX 4C QUARTERLYCASH FLOW REPORTFOR
ENTITIES SUBJECTTO LISTING RULE 4.7B (CONT.)
12 ASX:TTX | ABN: 72 607 771 077
APPENDIX 4C QUARTERLYCASH FLOW REPORTFOR
ENTITIES SUBJECTTO LISTING RULE 4.7B (CONT.)
13 ASX:TTX | ABN: 72 607 771 077
1.This statement has been prepared in accordance with accounting standards and policies which
comply with Listing Rule 19.11A.
2.This statement gives a true and fair view of the matters disclosed.
Date: 28 January 2026
Authorised by the Tetratherix Board
(Name of body or officer authorising release – see note 4)
Notes
1.This quarterly cash flow report and the accompanying activity report provide a basis for informing
the market about the entity’s activities for the past quarter, how they have been financed and the
effect this has had on its cash position. An entity that wishes to disclose additional information over
and above the minimum required under the Listing Rules is encouraged to do so.
2.If this quarterly cash flow report has been prepared in accordance with Australian Accounting
Standards, the definitions in, and provisions of, AASB 107: Statement of Cash Flows apply to this
report. If this quarterly cash flow report has been prepared in accordance with other accounting
standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard
applies to this report.
3.Dividends received may be classified either as cash flows from operating activities or cash flows
from investing activities, depending on the accounting policy of the entity.
4.If this report has been authorised for release to the market by your board of directors, you can insert
here: “By the board”. If it has been authorised for release to the market by a committee of your
board of directors, you can insert here: “By the [name of board committee – e.g. Audit and Risk
Committee]”. If it has been authorised for release to the market by a disclosure committee, you can
insert here: “By the Disclosure Committee”.
5.If this report has been authorised for release to the market by your board of directors and you wish
to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance
Council’s Corporate Governance Principles and Recommendations, the board should have
received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity
have been properly maintained, that this report complies with the appropriate accounting standards
and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed
on the basis of a sound system of risk management and internal control which is operating
effectively.
COMPLIANCE STATEMENT
ASXANNOUNCEMENT JANUARY28, 2026
14 ASX:TTX | ABN: 72 607 771 077
Share your feedback
Discover